Political Advocacy Made Easy at the LLS

I'm the first to admit that I'm not the greatest when it comes to lobbying my elected officials, even when the cause is dear to me. The process of writing a letter or email, determining where to send it, and believing that it'll make a difference—these things tend to deter me. And I don't think I'm alone.

Fortunately the Leukemia & Lymphoma Society makes it really easy by way of their Office of Public Policy and their Action Center.

When you go to the Action Center, you can see the legislation they're advocating and, after filling out a very brief profile, you can add your voice to the cause. Because you enter your address in the profile, the site takes care of determining who your elected officials are, at both the state and federal levels.

Right now, you can easily send an email to your elected officials urging them to take action on:

The Cancer Clinical Trials Act (S. 488 and H.R. 716), which "would prevent health care plans – both state-based and ERISA-based – from denying patients enrolled in clinical trials services that would have been covered under their plan had they participated in what is considered standard therapy."

The formation of a bipartisan Pediatric Cancer Caucus "to provide a voice for children in this country who are suffering from cancer. The caucus is still being formed and looking for members."

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap